Us Bancorp \De\ Coherus Bio Sciences, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 3,001 shares of CHRS stock, worth $2,850. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,001

Previous 3,001 -0.0%

Holding current value

$2,850

Previous $3,000 33.33%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 06, 2024	BUY	$1.58 - $2.51 $4,741 - $7,532	3,001 New	3,001 $5,000
Q3 2023 Nov 03, 2023	BUY	$3.74 - $5.45 $972 - $1,417	260 New	260 $0
Q1 2023 May 09, 2023	SELL	$5.89 - $10.52 $5,890 - $10,520	-1,000 Reduced 77.82%	285 $1,000
Q4 2022 Feb 13, 2023	SELL	$5.69 - $10.07 $244 - $433	-43 Reduced 3.24%	1,285 $10,000
Q3 2022 Oct 27, 2022	BUY	$7.17 - $13.87 $308 - $596	43 Added 3.35%	1,328 $13,000
Q2 2022 Aug 01, 2022	SELL	$5.86 - $13.23 $12,206 - $27,558	-2,083 Reduced 61.85%	1,285 $9,000
Q1 2022 May 11, 2022	SELL	$10.92 - $16.41 $5,165 - $7,761	-473 Reduced 12.31%	3,368 $44,000
Q4 2021 Feb 11, 2022	BUY	$15.81 - $18.99 $6,324 - $7,595	400 Added 11.62%	3,841 $61,000
Q3 2021 Nov 10, 2021	SELL	$12.68 - $17.79 $24,916 - $34,957	-1,965 Reduced 36.35%	3,441 $55,000
Q2 2021 Aug 05, 2021	BUY	$12.95 - $15.41 $33,229 - $39,542	2,566 Added 90.35%	5,406 $75,000
Q3 2020 Nov 10, 2020	BUY	$17.41 - $19.89 $3,743 - $4,276	215 Added 8.19%	2,840 $52,000
Q2 2020 Aug 07, 2020	BUY	$14.43 - $19.16 $37,878 - $50,295	2,625 New	2,625 $47,000
Q4 2017 Feb 02, 2018	SELL	$8.35 - $14.4 $83 - $144	-10 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$11.1 - $14.5 $111 - $145	10	10 $0

Others Institutions Holding CHRS

# of Institutions

130

Shares Held

67.8M

Call Options Held

1.68M

Put Options Held

91.8K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $73.8M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account